🚨 每日 OncoAlert 通讯现已从马德里 🇪🇸 正式上线 #ESMO26
免费注册 👉 https://buff.ly/N5gYtAc
每天早晨直接送达您的收件箱
#ESMO26 第一天资讯如下：
📌 NATALEE 6 年 OS
📌 PANKU-Breast01 + Lancet 发表
📌 KEYNOTE-866 与 ENERGIZE 在 MIBC 中均为阴性
📌 HERIZON-GEA-01 3 年 OS
面向同行……由同行打造 🤝
订阅 👉 http://OncoAlert360.com
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
2035 浏览 · 18 赞 · 12 转发 · 1 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- OncoAlert@OncoAlert
The listed trials are not the COMPLETE list of trials included. There are many more that will be there!
来源：OncoAlert · x.com